Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPC
May 2nd 2022The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.
Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Shows Efficacy, Tolerability in CLL
May 1st 2022The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.
Aliènne Salleroli on Establishing Equity, Diversity, and Inclusion Throughout Oncology Practice
April 29th 2022The framework for establishing equity, diversity, and inclusion throughout oncology nursing already exists within the standard for health and safety, explains Aliènne Salleroli, MS, BSN, RN, OCN.